Pridopidine Phase 3 Study in Huntington's Disease
This study is investigating a new drug, pridopidine, to see if it can slow down the progression of Huntington's disease (HD) in adults and if it's safe to use. Researchers want to know if pridopidine can improve overall symptoms of HD, including daily activities, thinking skills, movement, and quality of life over one year. Some participants will receive pridopidine, while others will get a placebo (a dummy pill with no active drug). Neither the participant nor the doctors will know who is getting which. All participants will take a pill twice a day for a year and have six clinic visits. After this first year, everyone will then receive pridopidine for two more years. This will help scientists understand how well the drug works.
De un vistazo
¿De qué trata este estudio?
Huntington's disease (HD) is a serious condition that affects the brain, causing problems with movement, thinking, and mental health. There isn't a cure yet, so researchers are constantly looking for new treatments that can slow down its effects or improve symptoms. This study focuses on a drug called pridopidine, aiming to see if it can help people with HD.
Specifically, the researchers want to find out two main things: firstly, whether pridopidine can slow down how much HD symptoms get worse over one year. Secondly, they want to understand if it helps with specific aspects of the disease, such as a person's ability to do daily tasks, their memory and thinking skills, their control over their body movements, and their overall quality of life. By comparing pridopidine to a placebo (a pill that looks the same but contains no active drug), they can get a clear picture of its potential benefits.
This type of study is really important because it helps doctors and patients understand if a new treatment is effective and safe. The information gathered from this research could lead to new ways to manage HD and potentially improve the lives of those living with the condition. It's a key step in bringing new medicines closer to people who need them.
Puntos clave
- This study explores pridopidine as a potential new treatment for Huntington's disease.
- It aims to see if the drug can slow down symptoms and is safe.
- Participants take a pill twice daily for three years.
- The first year involves either the drug or a dummy pill; everyone gets the drug for the next two years.
- Regular clinic visits and check-ups are part of participating.
- Your medical care will not be affected if you choose not to join or decide to leave the study.
¿Quién puede ser elegible?
To join this study, you would generally need to be an adult between 23 and 65 years old who has been diagnosed with Huntington's disease after the age of 21. Your diagnosis must be based on clear symptoms and a specific genetic test result.
There are also some medical conditions or medications that would prevent you from taking part. For example, if you have certain heart problems, a recent history of seizures, severe kidney or liver issues, or certain types of cancer, you might not be eligible. If you are pregnant, planning to become pregnant, or breastfeeding, you cannot join the study. Also, if you've recently used certain types of Huntington's disease medication or other specific drugs, you might not be able to participate.
The research team will carefully check all these details to make sure the study is safe for you and that the results will be clear and accurate. It’s important to remember that you shouldn't stop any current medication just to join this study.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Are you between 23 and 65 years old?
- Were you diagnosed with Huntington's disease (HD) after age 21?
- Have you not used certain specific HD medications (called ADMs) in the last six months?
- Are you not pregnant, planning to become pregnant, or breastfeeding?
- Do you not have severe heart, kidney, or liver problems, or certain other serious health issues?
¿En qué consiste la participación?
If you decide to join this study, here's what it would involve:
For the first year, you would take one study capsule (either pridopidine or a dummy pill) twice a day – once in the morning and once in the afternoon. During this year, you would visit the clinic six times for check-ups and tests. There will also be five phone calls with the study team to check on your safety.
After this initial year, all participants will then receive pridopidine for an additional two years. During these two years, you would continue to take pridopidine twice a day and would have six more clinic visits. The total duration of your participation in the study would be three years. Throughout the study, the medical team will be checking your health and how you're responding to the treatment.
Riesgos y beneficios potenciales
Locations (66)
- The University of Alabama at BirminghamCódigo postal verificadoBirmingham, United States· Reclutamiento
- University of California, San DiegoCódigo postal verificadoLa Jolla, Estados Unidos· Reclutamiento
- Centro Médico de UCLACódigo postal verificadoLos Angeles, United States· Aún no reclutando
- UC Davis Medical CenterCódigo postal verificadoSacramento, United States· Aún no reclutando
- Georgetown UniversityCódigo postal verificadoWashington D.C., Estados Unidos· Aún no reclutando
- University of Miami-U Health Boca RatonCódigo postal verificadoBoca Raton, Estados Unidos· Aún no reclutando
- University of Florida (Norman Fixel Institute for Neurological Diseases)Código postal verificadoGainesville, Estados Unidos· Aún no reclutando
- Northwestern UniversityCódigo postal verificadoChicago, Estados Unidos· Aún no reclutando
- Rush University Medical CenterCódigo postal verificadoChicago, Estados Unidos· Aún no reclutando
- Centro Médico de la Universidad de KansasCódigo postal verificadoKansas City, Estados Unidos· Aún no reclutando
- Hereditary Neurological Disease CentreCódigo postal verificadoWichita, Estados Unidos· Reclutamiento
- Johns Hopkins UniversityCódigo postal verificadoBaltimore, Estados Unidos· Aún no reclutando
Preguntas comunes
¿Cuál es el objetivo principal de este estudio?
The main goal is to see if the drug pridopidine can slow down how Huntington's disease gets worse and if it is safe for people to use.
¿Qué es un 'placebo'?
A placebo is a pill that looks exactly like the study drug but doesn't contain any active medicine. It helps researchers compare the real drug's effects.
¿Cuánto tiempo estaré en el estudio?
You would be in the study for a total of three years. The first year involves either pridopidine or a placebo, followed by two more years where everyone receives pridopidine.
Will I know if I'm getting the real drug or the placebo?
For the first year, neither you nor your doctors will know if you're receiving pridopidine or the placebo. This is to ensure fair and unbiased results.
What kind of visits will I have?
You will have regular clinic visits for check-ups and tests, as well as some safety phone calls, throughout the three years of the study.
Cómo obtener más información
Prilenia Medical Information
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.